Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors

Abstract

In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 µM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC₅₀ of 4.63±0.62 µg/mL, which was similar with that in EFV and TMC278 (IC₅₀ 7.76±0.37 and 1.57±0.20 µg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future.

Keywords

synthesis - quinoline - molecular docking - hybrid - anti HIV-1 activity

• References

• 1 Mathes T, Pieper D, Antoine SL. et al. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients–A systematic review. Hiv Med 2013; 14: 583-595
• 2 Slama L, Xiuhong Li, Brown T. et al. Increases in duration of first highly active antiretroviral therapy over time (1996–2009) and associated factors in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2014; 65: 57-64
• 3 Ashchop EL, Wainberg MA, Sloan RD. et al. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother 2012; 56: 5000-5008
• 4 Vivet-Boudou V, Didierjean J, Isel C. et al. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 2006; 63: 163-186
• 5 Pedersen OS, Pederson EB. Non-nucleoside reverse transcriptase inhibitors: The NNRTI boom. Antiviral Chem Chemother 1999; 10: 285-314
• 6 de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 2010; 85: 75-90
• 7 Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleside reverse transcriptase inhibitors. Virus Res 2008; 134: 147-156
• 8 Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol 2004; 36: 1735-1751
• 9 Mehellou Y, De Clercq E. Twenty-Six Years of anti-hiv drug discovery: Where do we stand and where do we go?. J Med Chem 2010; 53: 521-538
• 10 Ludovici DW, De Corte BL, Kukla MJ. et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001; 11: 2235-2239
• 11 Jannen PA, Lewi PJ, Arnold E. et al. In Search of a novel anti-HIV drug:  Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine). J Med Chem 2005; 48: 1901-1909
• 12 Kumar S, Bawa S, Gupta H. Biological activities of quinoline derivatives. Mini-Rev Med Chem 2009; 9: 1648-1654
• 13 Acharya BN, Thavaselvam D, Kaushik MP. Synthesis and antimalarial evaluation of novel pyridine quinoline hybrids. Med Chem Res 2008; 17: 487-494
• 14 Assefa H, Kamath S, Buolamwini JK. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aided Mol Des 2003; 17: 475-493
• 15 Baba A, Kawamura N, Makino H. et al. Studies on disease-modifying antirheumatic drugs: Synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect. J Med Chem 1996; 39: 5176-5182
• 16 Fernandez-Bachiller MI, Perez C, Gonzalez-Munoz GC. et al. Novel tacrine–8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper complexing properties. J Med Chem 2010; 53: 4927-4937
• 17 Jain S, Chandra V, Jain PK et al. Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem 2016 In press
• 18 Ukkonen P, Korpela J, Suni J. et al. Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays. Eur J Clin Microbiol & Infect Dis 1988; 7: 518-523
• 19 Reverse Transcriptase Assay. Colorimetric kit, Roche Diagnostics GmbH, Roche, Applied Science, Sandhofer Strasse. 116: D-68305 Mannheim, Germany:
• 20 Suzuki K, Craddock BP, Okamoto N. et al. Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase. J Virol Methods 1993; 44: 189-198
• 21 Mosman T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
• 22 Carmichael J, Degraff WG, Gazdar AF. et al. Evaluation of a tetrazolium-based semi-automated colormetric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942
• 23 Doyly A, Griffiths JB. Eds. Mammalian Cell Culture-essential Techniques. Chichester: Wiley & Sons; 1997
• 24 Tominaga MH, Ishiyama M, Ohseto F. et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 1999; 36: 47-50
• 25 Ren J, Nichols CE, Stamp A. et al. Structure insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS Journal 2006; 273: 3850-3860
• 26 Hecht M, Harrer T, Buttner M. et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS 2013; 27: 2031-2040
• 27 Sciamanna I, Landriscina M, Pittoggi C. et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005; 24: 3923-3931
• 28 Landriscina M, Fabiano A, Altamura S. et al. Reverse transcriptase inhibitors down-rehulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 2005; 90: 5663-5671
• 29 Mangiacasale R, Pittoggi C, Sciamanna I. et al. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 2003; 22: 2750-2761
• 30 Pittoggi C, Martis G, Mastrangeli G. et al. In vitro evidence for a new therapeutic approach in renal carcinoma. Int Braz J Urol 2008; 34: 492-502
• 31 Sciamanna I, Gualtieri A, Cossetti C. et al. A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget 2013; 4: 2271-2287
• 32 Sinibaldi-Vallebona P, Lavia P, Garaci E. et al. A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. Genes Chromosomes Cancer 2006; 45: 1-10
• 33 Stefanidis K, Loutradis D, Vassiliou LV. et al. Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecologic oncology 2008; 111: 344-349